Press Release

Back to Press Release List

ASGCT Poster Presentation: “Systematic identification of potent guide RNAs with minimal off-target activity for the CRISPR/Cas9 engineering of KSQ-001, and engineered Tumor Infiltrating Lymphocyte (eTIL™)”

Click image to enlarge.

Click to download PDF file.

© 2022 KSQ Therapeutics, Inc. All rights reserved.